SENSEI BIOTHERAPEUTICS INC (SNSE)
Institutional ownership reported to the SEC as of Q1 2025, across 17 quarters.
Calls and puts are the parts of reported value carried in derivative lines rather than shares, and they point in opposite directions: a manager holding calls is positioned for the security, one holding puts against it - or hedging shares they already own, which is why index funds carry so many. Most sites add the two together and report one figure, which averages away the only interesting part.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | $230.7K | 585,576 | 0.00% | 17q | -1.5%-$3.5K |
| Ikarian Capital, LLC | $177.3K | 449,963 | 0.02% | 4q | -30.8%-$78.8K |
| Catalio Capital Management, LP | $116.0K | 294,374 | 0.03% | 2q | HELD |
| RENAISSANCE TECHNOLOGIES LLC | $69.9K | 177,300 | 0.00% | 13q | +13.1%+$8.1K |
| GEODE CAPITAL MANAGEMENT, LLC | $59.4K | 150,709 | 0.00% | 17q | +1.2% |
| BOOTHBAY FUND MANAGEMENT, LLC | $42.8K | 108,658 | 0.00% | 4q | -37.1%-$25.3K |
| UBS Group AG | $16.8K | 42,541 | 0.00% | 2q | +2126950.0%+$16.8K |
| NORTHERN TRUST CORP | $10.2K | 25,983 | 0.00% | 17q | HELD |
| STATE STREET CORP | $10.2K | 25,774 | 0.00% | 17q | HELD |
| Cresset Asset Management, LLC | $7.8K | 19,671 | 0.00% | 5q | HELD |
| RAYMOND JAMES FINANCIAL INC | $5.5K | 14,000 | 0.00% | 2q | HELD |
| MORGAN STANLEY | $3.6K | 9,219 | 0.00% | 17q | HELD |
| Tower Research Capital LLC (TRC) | $2.1K | 5,404 | 0.00% | 17q | -0.8% |
| BARCLAYS PLC | $1.0K | 2,558 | 0.00% | new | NEW |
| JPMORGAN CHASE & CO | $276 | 702 | 0.00% | 17q | HELD |
| BNP PARIBAS FINANCIAL MARKETS | $63 | 160 | 0.00% | 2q | HELD |
| BANK OF AMERICA CORP /DE/ | $56 | 142 | 0.00% | 17q | +4.4% |
| CITIGROUP INC | $49 | 124 | 0.00% | new | NEW |
| SBI Securities Co., Ltd. | $36 | 92 | 0.00% | 2q | +29.6% |
What the insiders did
Open market purchases and sales reported on Form 4 in the last 180 days. Grants, option exercises and shares surrendered to cover tax are left out: they are compensation rather than a decision to buy or sell. Where a broker filled one order in tranches the lines are summed, because it was one decision.
Ten percent owners and entities
Usually an institution that crossed a reporting threshold, or a company taking a strategic stake, rather than an individual with a view.
| Date | Insider | Role | Side | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-01 | Peyer James | 10% owner, Other | Sold | 25,000 | $500.5K ×2 |
| 2026-06-01 | Cambrian BioPharma Inc | 10% owner | Sold | 25,000 | $500.5K ×2 |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 19 | $753.7K | 1,912,950 | 2 | 5 | 4 | 0.0% |
| Q4 2024 | 24 | $1.2M | 2,364,130 | 4 | 1 | 9 | 0.0% |
| Q3 2024 | 19 | $1.3M | 2,207,524 | 1 | 4 | 5 | 0.0% |
| Q2 2024 | 23 | $1.3M | 2,108,324 | 5 | 5 | 5 | 0.0% |
| Q1 2024 | 24 | $2.5M | 2,334,485 | 2 | 3 | 5 | 0.0% |
| Q4 2023 | 23 | $2.1M | 2,963,197 | 1 | 4 | 6 | 0.0% |
| Q3 2023 | 22 | $2.4M | 3,109,261 | 1 | 2 | 6 | 0.0% |
| Q2 2023 | 26 | $3.6M | 3,144,045 | 2 | 5 | 6 | 0.0% |
| Q1 2023 | 26 | $4.7M | 3,135,925 | 1 | 7 | 7 | 0.0% |
| Q4 2022 | 27 | $3.9M | 2,640,954 | 5 | 3 | 11 | 0.0% |
| Q3 2022 | 27 | $4.5M | 2,883,932 | 2 | 5 | 13 | 0.0% |
| Q2 2022 | 32 | $7.1M | 3,111,635 | 7 | 5 | 13 | 0.0% |
| Q1 2022 | 40 | $8.2M | 3,551,152 | 8 | 8 | 14 | 0.0% |
| Q4 2021 | 36 | $19.7M | 3,405,329 | 8 | 15 | 8 | 0.0% |
| Q3 2021 | 41 | $37.1M | 3,528,645 | 13 | 15 | 9 | 0.0% |
| Q2 2021 | 34 | $22.7M | 2,322,951 | 3 | 14 | 13 | 0.0% |
| Q1 2021 | 40 | $45.8M | 3,154,649 | 40 | 0 | 0 | 0.0% |